Kudos to Pam Belluck at the NYT for this opening paragraph - this is the right way to report on a story like lecanemab:

"The Food and Drug Administration on Friday approved a new #Alzheimer’s drug that may modestly slow the pace of cognitive decline early in the disease, but also carries risks of swelling and bleeding in the brain."

https://www.nytimes.com/2023/01/06/health/alzheimers-drug-leqembi-lecanemab.html